BridgeBio Pharma (FRA:2CL) Inventory Turnover: 0.33 (As of Mar. 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €64.52
GF Value €126.05
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Inventory Turnover?

BridgeBio Pharma FRA:2CL -0.08% 66 Inventory Turnover is 0.33 as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €126.05 (Possible Value Trap). The stock has 8 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. BridgeBio Pharma's Cost of Goods Sold for the three months ended in Mar. 2026 was €8.6 Mil. BridgeBio Pharma's Average Total Inventories for the quarter that ended in Mar. 2026 was €25.7 Mil. BridgeBio Pharma's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.33.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BridgeBio Pharma's Days Inventory for the three months ended in Mar. 2026 was 272.65.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BridgeBio Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.15.

BridgeBio Pharma  (FRA:2CL) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BridgeBio Pharma's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=25.6875/8.597*365 / 4
=272.65

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BridgeBio Pharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=25.6875 / 168.255
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

BridgeBio Pharma Inventory Turnover Related Terms

BridgeBio Pharma Inventory Turnover Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma Inventory Turnover Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.78

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.32 0.30 0.32 0.33
FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Pharma Inventory Turnover Calculation

BridgeBio Pharma's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=17.902 / ((0 + 22.847) / 1 )
=17.902 / 22.847
=0.78

BridgeBio Pharma's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=8.597 / ((22.847 + 28.528) / 2 )
=8.597 / 25.6875
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.33 mean?
BridgeBio Pharma (FRA:2CL) has a Inventory Turnover of 0.33 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's Inventory Turnover too high?
BridgeBio Pharma's current Inventory Turnover is 0.33. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Inventory Turnover compare to EXEL and IONS?
BridgeBio Pharma's Inventory Turnover of 0.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Inventory Turnover is 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €126.05, compared to a current price of €64.52 — trading 48.8% below its estimated fair value. The current Inventory Turnover is 0.33. BridgeBio Pharma's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Inventory Turnover is 0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €64.52 is trading 48.8% below its estimated GF Value™ of €126.05. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Inventory Turnover: 0.33
  • GF Value™: €126.05 vs. price of €64.52 (48.8% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.52
Price
€126.05
GF Value